Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Debourdeau

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
BMJ Supportive & Palliative Care|November 6, 2020
Identification of factors associated with aggressive end-of-life antitumour treatment: retrospective study of 1282 patients with cancerPhilippe Debourdeau, Mohamed Belkacémi, Guillaume Economos, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|June 26, 2026
API-CAT Investigators' Decisions on Anticoagulation following Extended Treatment for Cancer VTEIsabelle Mahé, Florent Happe, Manuel Monreal, et al.
British Journal of Haematology|June 2, 2021
Risk of recurrent venous thromboembolism in patients with autoimmune diseases: data from the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) registryJaime Borjas Howard, Pablo Ruiz-Sada, Karina de Leeuw, et al.
Cancer Medicine|October 6, 2017
Incidence, risk factors, and outcomes of central venous catheter-related thromboembolism in breast cancer patients: the CAVECCAS studyPhilippe Debourdeau, Marc Espié, Sylvie Chevret, et al.
Bulletin Du Cancer|August 12, 2018
[Supportive care for survivors]Grégory Ninot, Philippe Debourdeau, Françoise Blanc-Legier, et al.
The Oncologist|July 3, 2021
A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic ChemotherapyLaurent Zelek, Philippe Debourdeau, Hugues Bourgeois, et al.
Cancers|April 13, 2023
Three-Month Outcomes in Cancer Patients with Superficial or Deep Vein Thrombosis in the Lower Limbs: Results from the RIETE RegistryPhilippe Debourdeau, Laurent Bertoletti, Carme Font, et al.
Medicine|August 13, 2015
Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous ThromboembolismDominique Farge, Javier Trujillo-Santos, Philippe Debourdeau, et al.
Angiology|October 4, 2019
Venous Thromboembolism in Patients With Autoimmune Disorders: Findings From the RIETE RegistryPablo Ruiz Sada, Juan J López-Núñez, Angel Samperiz, et al.
Thrombosis and Haemostasis|April 20, 2021
Failure of the Ottawa Score to Predict the Risk of Recurrent Venous Thromboembolism in Cancer Patients: The Prospective PREDICARE Cohort StudyPhilippe Girard, Silvy Laporte, Céline Chapelle, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
BMJ Supportive & Palliative Care|November 6, 2020
Identification of factors associated with aggressive end-of-life antitumour treatment: retrospective study of 1282 patients with cancerPhilippe Debourdeau, Mohamed Belkacémi, Guillaume Economos, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|June 26, 2026
API-CAT Investigators' Decisions on Anticoagulation following Extended Treatment for Cancer VTEIsabelle Mahé, Florent Happe, Manuel Monreal, et al.
British Journal of Haematology|June 2, 2021
Risk of recurrent venous thromboembolism in patients with autoimmune diseases: data from the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) registryJaime Borjas Howard, Pablo Ruiz-Sada, Karina de Leeuw, et al.
Cancer Medicine|October 6, 2017
Incidence, risk factors, and outcomes of central venous catheter-related thromboembolism in breast cancer patients: the CAVECCAS studyPhilippe Debourdeau, Marc Espié, Sylvie Chevret, et al.
Bulletin Du Cancer|August 12, 2018
[Supportive care for survivors]Grégory Ninot, Philippe Debourdeau, Françoise Blanc-Legier, et al.
The Oncologist|July 3, 2021
A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic ChemotherapyLaurent Zelek, Philippe Debourdeau, Hugues Bourgeois, et al.
Cancers|April 13, 2023
Three-Month Outcomes in Cancer Patients with Superficial or Deep Vein Thrombosis in the Lower Limbs: Results from the RIETE RegistryPhilippe Debourdeau, Laurent Bertoletti, Carme Font, et al.
Medicine|August 13, 2015
Fatal Events in Cancer Patients Receiving Anticoagulant Therapy for Venous ThromboembolismDominique Farge, Javier Trujillo-Santos, Philippe Debourdeau, et al.
Angiology|October 4, 2019
Venous Thromboembolism in Patients With Autoimmune Disorders: Findings From the RIETE RegistryPablo Ruiz Sada, Juan J López-Núñez, Angel Samperiz, et al.
Thrombosis and Haemostasis|April 20, 2021
Failure of the Ottawa Score to Predict the Risk of Recurrent Venous Thromboembolism in Cancer Patients: The Prospective PREDICARE Cohort StudyPhilippe Girard, Silvy Laporte, Céline Chapelle, et al.
Pageof 7